Publications of Martin Begemann

Tantra, M.; Hammer, C.; Kästner, A.; Dahm, L.; Begemann, M.; Bodda, C.; Hammerschmidt, K.; Giegling, I.; Stepniak, B.; Castillo Venzor, A. et al.; Konte, B.; Erbaba, B.; Hartmann, A.; Tarami, A.; Schulz-Schaeffer, W.; Rujescu, D.; Mannan, A. U.; Ehrenreich, H.: Mild expression differences of MECP2 influencing aggressive social behavior. EMBO Molecular Medicine 6 (5), pp. 662 - 684 (2014)

Kästner, A.; Malzahn, D.; Begemann, M.; Hilmes, C.; Bickeböller, H.; Ehrenreich, H.: Odor naming and interpretation performance in 881 schizophrenia subjects: association with clinical parameters. BMC Psychiatry 13, 218 (2013)

Wojcik, S. M.; Tantra, M.; Stepniak, B.; Man, K.-n. M.; Müller-Ribbe, K.; Begemann, M.; Ju, A.; Papiol, S.; Ronnenberg, A.; Gurvich, A. et al.; Shin, Y.; Augustin, I.; Brose, N.; Ehrenreich, H.: Genetic markers of Munc13 protein family member, BAIAP3, are gender-specifically associated with anxiety and benzodiazepine abuse in mouse and man. Molecular Medicine 19, pp. 135 - 148 (2013)

El-Kordi, A.; Kästner, A.; Grube, S.; Klugmann, M.; Begemann, M.; Sperling, S.; Hammerschmidt, K.; Hammer, C.; Stepniak, B.; Patzig, J. et al.; Monasterio-Schrader, P. d.; Strenzke, N.; Flügge, G.; Werner, H. B.; Pawlak, R.; Nave, K.-A.; Ehrenreich, H.: A single gene defect causing claustrophobia. Translational Psychiatry 3, e254 (2013)

Hagemeyer, N.; Goebbels, S.; Papiol, S.; Kästner, A.; Hofer, S.; Begemann, M.; Gerwig, U. C.; Boretius, S.; Wieser, G. L.; Ronnenberg, A. et al.; Gurvich, A.; Heckers, S. H.; Frahm, J.; Nave, K.-A.; Ehrenreich, H.: A myelin gene causative of a catatonia-depression syndrome upon aging. Embo Molecular Medicine 4 (6), pp. 528 - 539 (2012)

Kästner, A.; Grube, S.; El-Kordi, A.; Stepniak, B.; Friedrichs, H.; Sargin, D.; Schwitulla, J.; Begemann, M.; Giegling, I.; Miskowiak, K. W. et al.; Sperling, S.; Hannke, K.; Ramin, A.; Heinrich, R.; Gefeller, O.; Nave, K.-A.; Rujescu, D.; Ehrenreich, H.: Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Molecular Medicine 18, pp. 1029 - 1040 (2012)

Papiol, S.; Malzahn, D.; Kästner, A.; Sperling, S.; Begemann, M.; Stefansson, H.; Bickeböller, H.; Nave, K.-A.; Ehrenreich, H.: Dissociation of accumulated genetic risk and disease severity in patients with schizophrenia. Translational Psychiatry, e45 (2011)

Ribbe, K.; Ackermann, V.; Schwitulla, J.; Begemann, M.; Papiol, S.; Grube, S.; Sperling, S.; Friedrichs, H.; Jahn, O.; Sillaber, I. et al.; Gefeller, O.; Krampe, H.; Ehrenreich, H.: Prediction of the risk of comorbid alcoholism in schizophrenia by interaction of common genetic variants in the corticotropin-releasing factor system. Archives of General Psychiatry 68 (12), pp. 1247 - 1256 (2011)

Papiol, S.; Begemann, M.; Rosenberger, A.; Friedrichs, H.; Ribbe, K.; Grube, S.; Schwab, M. H.; Jahn, H.; Gunkel, S.; Benseler, F. et al.; Nave, K.-A.; Ehrenreich, H.: A phenotype-based genetic association study reveals the contribution of neuregulin1 gene variants to age of onset and positive symptom severity in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156 (3), pp. 340 - 345 (2011)

Grube, S.; Gerchen, M. F.; Adamcio, B.; Pardo, L. A.; Martin, S.; Malzahn, D.; Papiol, S.; Begemann, M.; Ribbe, K.; Friedrichs, H. et al.; Radyushkin, K. A.; Müller, M.; Benseler, F.; Riggert, J.; Falkai, P.; Bickeböller, H.; Nave, K.-A.; Brose, N.; Stühmer, W.; Ehrenreich, H.: A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia. Embo Molecular Medicine 3 (6), pp. 309 - 319 (2011)

Wüstenberg, T.; Begemann, M.; Bartels, C.; Gefeller, O.; Stawicki, S.; Hinze-Selch, D.; Mohr, A.; Falkai, P.; Aldenhoff, J. B.; Knauth, M. et al.; Nave, K.-A.; Ehrenreich, H.: Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Molecular Psychiatry 16 (1), pp. 26 - 36 (2011)

Wüstenberg, T.; Begemann, M.; Bartels, C.; Gefeller, O.; Stawicki, S.; Hinze-Selch, D.; Mohr, A.; Falkai, P.; Aldenhoff, J.; Knauth, M. et al.; Nave, K. A.; Ehrenreich, H.: EPO treatment preserves gray matter in discrete brain regions of chronic schizophrenic patients: indication of areas with most progressive neurodegeneration inherent to the disease process. Molecular Psychiatry 16, 1 (2011)

Ribbe, K.; Friedrichs, H.; Begemann, M.; Grube, S.; Papiol, S.; Kästner, A.; Gerchen, M. F.; Ackermann, V.; Tarami, A.; Treitz, A. et al.; Flögel, M.; Adler, L.; Aldenhoff, J. B.; Becker-Emner, M.; Becker, T.; Czernik, A.; Dose, M.; Folkerts, H.; Freese, R.; Guenther, R.; Herpertz, S.; Hesse, D.; Kruse, G.; Kunze, H.; Franz, M.; Lohrer, F.; Maier, W.; Mielke, A.; Müller-Isberner, R.; Oestereich, C.; Pajonk, F.-G.; Pollmächer, T.; Schneider, U.; Schwarz, H.-J.; Kröner-Herwig, B.; Havemann-Reinecke, U.; Frahm, J.; Stühmer, W.; Falkai, P.; Brose, N.; Nave, K.-A.; Ehrenreich, H.: The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry 10, 91 (2010)

Begemann, M.; Grube, S.; Papiol, S.; Malzahn, D.; Krampe, H.; Ribbe, K.; Friedrichs, H.; Radyushkin, K. A.; El-Kordi, A.; Benseler, F. et al.; Hannke, K.; Sperling, S.; Schwerdtfeger, D.; Thanhäuser, I.; Gerchen, M. F.; Ghorbani, M.; Gutwinski, S.; Hilmes, C.; Leppert, R.; Ronnenberg, A.; Sowislo, J.; Stawicki, S.; Stödtke, M.; Szuszies, C.; Reim, K.; Riggert, J.; Eckstein, F.; Falkai, P.; Bickeböller, H.; Nave, K.-A.; Brose, N.; Ehrenreich, H.: Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Archives of General Psychiatry 67 (9), pp. 879 - 888 (2010)

Begemann, M.; Sargin, D.; Rossner, M. J.; Bartels, C.; Theis, F.; Wichert, S. P.; Stender, N.; Fischer, B.; Sperling, S.; Stawicki, S. et al.; Wiedl, A.; Falkai, P.; Nave, K.-A.; Ehrenreich, H.: Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Molecular Medicine 14 (9-10), pp. 546 - 552 (2008)